Princeton

LianBio Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Retrieved on: 
Thursday, December 9, 2021
U.S. Securities and Exchange Commission, Johnson & Johnson, Oxford Handbook of Clinical Medicine, Global, Forward-looking statement, Company, Research, G&A, GLOBE, SEC, Biotechnology, Gene amplification, Exercise, Pfizer, FGFR, Ophthalmology, Leadership, FGFR2, NBTXR3, IPO, Food, PDUFA, Patient, American depositary receipt, Sinusitis, ADSS, Inflammation, Emerging market, R, Prescription Drug User Fee Act, BMS, MBBS, ADS, DB, Clinical trial, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Sale, Cisplatin, Life insurance, Pharmaceutical industry

SHANGHAI, China and PRINCETON, N.J., Dec. 09, 2021 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today provided a corporate update and reported financial results for the third quarter ended September 30, 2021.

Key Points: 
  • Recent Business Highlights and Clinical Development Updates:
    In November, LianBio initiated and completed enrollment and dosing in a pharmacokinetic (PK) study of mavacamten in healthy Chinese volunteers.
  • In October, LianBio appointed Jesse Wu to the Companys Board of Directors.
  • In August, LianBio appointed Pascal Qian as China General Manager to build out the Companys operations and commercial infrastructure.
  • Third Quarter 2021 Financial Results:
    R&D expenses were $4.7 million for the three months ended September 30, 2021, as compared to $116.9 million for the three months ended September 30, 2020.

Advaxis Issues Letter to Stockholders Regarding Recent Special Meeting Results

Retrieved on: 
Thursday, December 9, 2021
Twitter, Listeria monocytogenes, Risk, Company, Agreement, Forward-looking statement, Prospectus, SEC, Securities Act of 1933, Immunotherapy, Corporate action, Technology, YouTube, Immune system, Attention, Tripura Merger Agreement, Form, Securities Exchange Act of 1934, Plan, Proxy, Shareholder, VP, Adoption, LM, Neoplasm, Documentation, Facebook, Goal, LinkedIn, Form 8-K, Tumor microenvironment, Person, Annual report

MONMOUTH JUNCTION, N.J., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today issued the following statement to stockholders:

Key Points: 
  • Advaxis, Inc.is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products.
  • The definitive proxy statement / prospectus was mailed to Advaxis stockholders of record as of September 17, 2021.
  • Completion of the proposed transactions is subject to approval by the stockholders of Advaxis, Inc. and certain other conditions.
  • The proposed business combination is expected to close shortly after the special meeting assuming all conditions are met.

Certara to Host Investor Day on December 15, 2021

Retrieved on: 
Wednesday, December 8, 2021
Drug discovery, Investor relations, Certara, Simulation, GLOBE, Nasdaq, Technology, Software

PRINCETON, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, will host an Investor Day on Wednesday, December 15, 2021 from 3:00 PM to 6:00 PM ET in New York City.

Key Points: 
  • PRINCETON, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, will host an Investor Day on Wednesday, December 15, 2021 from 3:00 PM to 6:00 PM ET in New York City.
  • Certaras management team will provide updates on the Companys strategy, differentiated software and technology-driven services, and financial guidance for 2022.
  • The live video webcast of the event, along with a slide presentation, will be available on Certara's Investor Relations website at https://ir.certara.com/events/event-details/certara-investor-day .
  • A replay of the event will be archived on the Investor Relations website for 2 weeks following the event.

Coface Launches Non-cancellable Trade Credit Insurance Team in North America

Retrieved on: 
Friday, December 3, 2021
Insurance, CEO, Compagnie Française d'Assurance pour le Commerce Extérieur, GLOBE, Head, Excess, Eduardo Xol

Princeton, New Jersey, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Coface, a leadingtrade credit insurer, is launching a new team to enhance non-cancellable credit insurance offerings in the North America Region.

Key Points: 
  • Princeton, New Jersey, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Coface, a leadingtrade credit insurer, is launching a new team to enhance non-cancellable credit insurance offerings in the North America Region.
  • Ryan Cummings joined Coface North America this week as Head of XoL (Excess of Loss).
  • Ryan comes to Coface with extensive experience in trade credit insurance underwriting and will lead the newly formed team.
  • Expanding our product suite to include a broader range of non-cancellable trade credit insurance offerings fits within our Build to Lead Strategic plan said Oscar Villalonga, Coface North America President and CEO.

Certara Announces Release of Simcyp™ Simulator Version 21, Expanding Capabilities to Align with Recent Regulatory Guidances

Retrieved on: 
Thursday, December 2, 2021
Trial of the century, Genotype, CEO, Behavior, PBPK, US Food Sovereignty Alliance, Technology, Industry, Lactation, Cerebrospinal fluid, Therapy, Pregnancy, Nasdaq, GLOBE, Drug, FDA, Pediatrics, Progestogen, Drug development, Doctor of Philosophy, Drug discovery, Pharmaceutical industry, Medical device

We are excited to offer new capabilities to advance modern drug development with the launch of our latest Simcyp Simulator, said William F. Feehery, Ph.D., CEO of Certara.

Key Points: 
  • We are excited to offer new capabilities to advance modern drug development with the launch of our latest Simcyp Simulator, said William F. Feehery, Ph.D., CEO of Certara.
  • This latest update aligns with recent regulatory guidances, so that we can help accelerate the development and approval of crucial therapies to patients.
  • Version 21 also features updates to Simcyp modules for pediatrics, pregnancy, lactation, biologic drugs, virtual bioequivalence and in vitro-in vivo correlation.
  • Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.

Oyster Point Pharma to Participate in the Piper Sandler 33rd Annual Healthcare Conference

Retrieved on: 
Wednesday, December 1, 2021
Patient, Conference, Company, Nasdaq, Twitter, Research, GLOBE, IgG4-related ophthalmic disease, Oyster Point, Piper Sandler Companies, Science, LinkedIn, Duane syndrome, Pharmaceutical industry

PRINCETON, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery,developmentand commercialization of first-in-class pharmaceutical therapies to treatophthalmicdiseases, today announced that the Company will participate virtually in the Piper Sandler 33rd Annual Healthcare Conference on Thursday, December 2, 2021.

Key Points: 
  • PRINCETON, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery,developmentand commercialization of first-in-class pharmaceutical therapies to treatophthalmicdiseases, today announced that the Company will participate virtually in the Piper Sandler 33rd Annual Healthcare Conference on Thursday, December 2, 2021.
  • Presentations areavailable for registered attendees via the Piper Sandler conference site
    Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.
  • In October 2021,Oyster Point Pharma received FDAapproval for TYRVAYA(varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease.
  • Oyster Point has a growing pipeline of clinical and pre-clinical programs and continues to expand its research and development pipeline through internal innovation and external collaborations.

Certara Announces Update of D360™ Scientific Informatics Software

Retrieved on: 
Monday, November 29, 2021
Research, Language, Technology, Industry, HELM, Hierarchy, Nasdaq, GLOBE, Biotechnology, Efficiency, Certara, Drug discovery, Intelligence, Fine chemical

State of the art intelligence technology for scientific informatics disciplines, like the D360 software, is a fundamental building block for the next generation digitalization, said Jim Brown, president of Digital Innovation Research at research firm Tech-Clarity.

Key Points: 
  • State of the art intelligence technology for scientific informatics disciplines, like the D360 software, is a fundamental building block for the next generation digitalization, said Jim Brown, president of Digital Innovation Research at research firm Tech-Clarity.
  • Certaras D360 scientific informatics software is used globally by more than 6,000 discovery research scientists at biopharmaceutical and biotechnology companies, including five of the top 10 by research and development spend.
  • The D360 software delivers end-to-end access to data and integrated scientific intelligence, resulting in timelier insights and greater understanding of drug candidates.
  • Certara accelerates medicines using proprietary biosimulation software and scientific intelligence technologies that transform traditional drug discovery and development.

Advaxis Issues Letter and Second Video Message to Stockholders Regarding Upcoming Special Meeting

Retrieved on: 
Wednesday, November 24, 2021
Agreement, LM, Listeria monocytogenes, Adoption, Securities Act of 1933, Technology, Annual report, Forward-looking statement, Company, Neoplasm, Form, Tumor microenvironment, SEC, Shareholder, Proxy, VP, Goal, Prospectus, Securities Exchange Act of 1934, Twitter, Attention, Tripura Merger Agreement, Risk, Corporate action, Form 8-K, Plan, Person, YouTube, Immunotherapy, LinkedIn, Immune system, Documentation, Facebook

MONMOUTH JUNCTION, N.J., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today issued the following statement to stockholders:

Key Points: 
  • Advaxis, Inc.is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products.
  • The definitive proxy statement / prospectus was mailed to Advaxis stockholders of record as of September 17, 2021.
  • Completion of the proposed transactions is subject to approval by the stockholders of Advaxis, Inc. and certain other conditions.
  • The proposed business combination is expected to close shortly after the special meeting assuming all conditions are met.

Oyster Point Pharma Announces Expansion of Executive Leadership Team to Support Commercialization of Tyrvaya™ (varenicline solution) Nasal Spray for the Signs and Symptoms of Dry Eye Disease

Retrieved on: 
Wednesday, November 24, 2021
Patient, University of Pittsburgh School of Law, Nach, University School, Michigan, Novartis, Sneeze, Compliance, New York University School of Law, General counsel, Pennsylvania State University, Homeostasis, University, Cough, Corporation, Wilfrid Sellars, JD, IgG4-related ophthalmic disease, Nasdaq, Twitter, Research, GLOBE, Psychology, Parasympathetic nervous system, Oyster Point, LLM, Throat irritation, FDA, Science, LinkedIn, Nasal spray, Nose, Trigeminal nerve, Duane syndrome, CCEP, Pharmaceutical industry, Management

Our focus at Oyster Point Pharma is to commercialize TyrvayaTM (varenicline solution) Nasal Spray and rapidly advance our pipeline forward.

Key Points: 
  • Our focus at Oyster Point Pharma is to commercialize TyrvayaTM (varenicline solution) Nasal Spray and rapidly advance our pipeline forward.
  • We look forward to their counsel as continue to build Oyster Point into a leading company in the eye care space.
  • TYRVAYA (varenicline solution) Nasal Spray 0.03 mg (formerly referred to as OC-01 nasal spray) is a highly selective cholinergic agonist that is FDA-approved to treat the signs and symptoms of dry eye disease as a multidose nasal spray.
  • In October 2021, Oyster Point Pharma received FDA approval for TYRVAYATM (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease.

Certara Announces Closing of Public Offering of Common Stock

Retrieved on: 
Monday, November 22, 2021
Security (finance), Sale, Varick Street, Technology, Jefferies Group, Form, 3rd Floor, U.S. Securities and Exchange Commission, Telephone, Prospectus, Nasdaq, Attention, GLOBE, LLC, BofA Securities, 2nd Floor (Nina song), Madison Avenue, Certara, Barclays, Drug discovery

PRINCETON, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the closing of its underwritten public offering of 10,000,000 shares of its common stock by certain existing stockholders at a public offering price of $31.00 per share.

Key Points: 
  • PRINCETON, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the closing of its underwritten public offering of 10,000,000 shares of its common stock by certain existing stockholders at a public offering price of $31.00 per share.
  • The selling stockholders have granted the underwriters a 30-day option to purchase up to 1,500,000 additional shares of common stock.
  • Certara did not receive any proceeds from the sale of shares in the offering by the selling stockholders.
  • Certara accelerates medicines using proprietary biosimulation software and technology to transform traditional drug discovery and development.